{
    "eid": "2-s2.0-85125938905",
    "title": "Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccine regimens in healthy adults: a prospective cohort study",
    "cover-date": "2022-01-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Immunology and Allergy",
            "@code": "2723",
            "@abbrev": "MEDI"
        },
        {
            "@_fa": "true",
            "$": "Immunology",
            "@code": "2403",
            "@abbrev": "IMMU"
        },
        {
            "@_fa": "true",
            "$": "Pharmacology",
            "@code": "3004",
            "@abbrev": "PHAR"
        }
    ],
    "keywords": [
        "adults",
        "COVID-19",
        "Heterologous",
        "homologous",
        "inactivated",
        "vaccine",
        "viral vectored"
    ],
    "authors": [
        "Nasamon Wanlapakorn",
        "Nungruthai Suntronwong",
        "Harit Phowatthanasathian",
        "Ritthideach Yorsaeng",
        "Preeyaporn Vichaiwattana",
        "Thanunrat Thongmee",
        "Chompoonut Auphimai",
        "Donchida Srimuan",
        "Thaksaporn Thatsanatorn",
        "Suvichada Assawakosri",
        "Sitthichai Kanokudom",
        "Yong Poovorawan"
    ],
    "citedby-count": 32,
    "ref-count": 39,
    "ref-list": [
        "Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination",
        "Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial",
        "Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial",
        "Neutralization of the SARS-CoV-2 Delta variant after heterologous and homologous BNT162b2 or ChAdOx1 nCoV-19 vaccination",
        "Serendipitous COVID-19 vaccine-mix in Uttar Pradesh, India: safety and immunogenicity assessment of a heterologous regime",
        "Heterologous prime-boost immunization with CoronaVac and Convidecia",
        "Thailand sticks with Sinovac vaccine after cases of \u2018stroke-like\u2019 side effects",
        "Immunogenicity of heterologous prime/booster-inactivated and adenoviral-vectored COVID-19 vaccine: real-world data",
        "Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data",
        "A phase III, observer-blind, randomized, placebo-controlled study of the efficacy, safety, and immunogenicity of SARS-CoV-2 inactivated vaccine in healthy adults aged 18-59 years: an interim analysis in Indonesia",
        "Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey",
        "Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates",
        "Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection",
        "Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination",
        "Heterologous ChAdOx1-S/BNT162b2 vaccination: neutralizing antibody response to SARS-CoV-2",
        "Safety and immunogenicity of inactivated COVID-19 vaccine in health care workers",
        "Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study",
        "Evolutionary dynamics of SARS-CoV-2 nucleocapsid protein and its consequences",
        "Long-term specific IgG response to SARS-CoV-2 nucleocapsid protein in recovered COVID-19 patients",
        "Development of an inactivated vaccine candidate for SARS-CoV-2",
        "Human IgG and IgA responses to COVID-19 mRNA vaccines",
        "COVID\u201119 vaccination and IgG and IgA antibody dynamics in healthcare workers",
        "Evolution of antibody immunity to SARS-CoV-2",
        "Immunogenicity of a third dose viral-vectored COVID-19 vaccine after receiving two-dose inactivated vaccines in healthy adults",
        "IgA dominates the early neutralizing antibody response to SARS-CoV-2",
        "Safety and Immunogenicity of an inactivated SARS-CoV-2 vaccine in a subgroup of healthy adults in Chile",
        "COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses",
        "Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial",
        "Preliminary evaluation of QuantiFERON SARS-CoV-2 and QIAreach anti-SARS-CoV-2 total test in recently vaccinated individuals",
        "Robust SARS-CoV-2-specific T cell immunity is maintained at 6 months following primary infection",
        "Memory T cell responses targeting the SARS coronavirus persist up to 11 years post-infection",
        "Limited and short-lasting virus neutralizing titers induced by inactivated SARS-CoV-2 vaccine",
        "Thailand cites positive results from Sinovac-AstraZeneca vaccine formula"
    ],
    "affiliation": [
        {
            "affiliation-city": "Bangkok",
            "@id": "60002620",
            "affilname": "Faculty of Medicine, Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002620",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "126510119",
            "affilname": "FRS(T)",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/126510119",
            "affiliation-country": "Thailand"
        }
    ],
    "funding": [
        "Department of Disease Control",
        "King Chulalongkorn Memorial Hospital",
        "Chulalongkorn University",
        "Ministry of Public Health",
        "National Research Council of Thailand",
        "Health Systems Research Institute"
    ]
}